RU2014133069A - Транслокации r-спондина и способы с их использованием - Google Patents
Транслокации r-спондина и способы с их использованием Download PDFInfo
- Publication number
- RU2014133069A RU2014133069A RU2014133069A RU2014133069A RU2014133069A RU 2014133069 A RU2014133069 A RU 2014133069A RU 2014133069 A RU2014133069 A RU 2014133069A RU 2014133069 A RU2014133069 A RU 2014133069A RU 2014133069 A RU2014133069 A RU 2014133069A
- Authority
- RU
- Russia
- Prior art keywords
- individual
- malignant tumor
- translocation
- spondin
- wnt pathway
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 claims abstract 30
- 230000005945 translocation Effects 0.000 claims abstract 28
- 238000000034 method Methods 0.000 claims abstract 23
- 102000013814 Wnt Human genes 0.000 claims abstract 22
- 108050003627 Wnt Proteins 0.000 claims abstract 22
- 239000005557 antagonist Substances 0.000 claims abstract 22
- 230000037361 pathway Effects 0.000 claims abstract 20
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 10
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract 6
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 claims 3
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 claims 3
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 claims 3
- 102100022762 R-spondin-1 Human genes 0.000 claims 3
- 102100022763 R-spondin-2 Human genes 0.000 claims 3
- 102100022766 R-spondin-3 Human genes 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 2
- 101000825962 Homo sapiens R-spondin-4 Proteins 0.000 claims 1
- 102100022759 R-spondin-4 Human genes 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000029565 malignant colon neoplasm Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ лечения злокачественной опухоли у индивидуума, включающий введение индивидууму эффективного количества антагониста пути wnt, причем лечение основано на том, что индивидуум со злокачественной опухолью содержит транслокацию R-спондина.2. Способ лечения клетки злокачественной опухоли, при котором клетка злокачественной опухоли содержит транслокацию R-спондина, включающий предоставление эффективного количества антагониста пути wnt.3. Способ лечения злокачественной опухоли у индивидуума, где было установлено наличие у индивидуума злокачественной опухоли, содержащей транслокацию R-спондина, включающий введение индивидууму эффективного количества антагониста пути wnt.4. Способ лечения злокачественной опухоли у индивидуума, включающий: определение того, что образец, полученный от индивидуума, содержит транслокацию R-спондина, и введение эффективного количества противоракового лекарственного средства, содержащего антагонист пути wnt, индивидууму, посредством чего злокачественная опухоль подвергается лечению.5. Способ лечения злокачественной опухоли, включающий: (а) отбор индивидуума со злокачественной опухолью, причем злокачественная опухоль содержит транслокацию R-спондина; и (b) введение таким образом выбранному индивидууму эффективного количества антагониста пути wnt, посредством чего злокачественная опухоль подвергается лечению.6. Способ идентификации индивидуума со злокачественной опухолью, который более или менее вероятно будет проявлять пользу от лечения с противораковым лекарственным средством, содержащим антагонист пути wnt, включающий: определение наличия или отсутствия транслокации R-спондина в полученном о
Claims (17)
1. Способ лечения злокачественной опухоли у индивидуума, включающий введение индивидууму эффективного количества антагониста пути wnt, причем лечение основано на том, что индивидуум со злокачественной опухолью содержит транслокацию R-спондина.
2. Способ лечения клетки злокачественной опухоли, при котором клетка злокачественной опухоли содержит транслокацию R-спондина, включающий предоставление эффективного количества антагониста пути wnt.
3. Способ лечения злокачественной опухоли у индивидуума, где было установлено наличие у индивидуума злокачественной опухоли, содержащей транслокацию R-спондина, включающий введение индивидууму эффективного количества антагониста пути wnt.
4. Способ лечения злокачественной опухоли у индивидуума, включающий: определение того, что образец, полученный от индивидуума, содержит транслокацию R-спондина, и введение эффективного количества противоракового лекарственного средства, содержащего антагонист пути wnt, индивидууму, посредством чего злокачественная опухоль подвергается лечению.
5. Способ лечения злокачественной опухоли, включающий: (а) отбор индивидуума со злокачественной опухолью, причем злокачественная опухоль содержит транслокацию R-спондина; и (b) введение таким образом выбранному индивидууму эффективного количества антагониста пути wnt, посредством чего злокачественная опухоль подвергается лечению.
6. Способ идентификации индивидуума со злокачественной опухолью, который более или менее вероятно будет проявлять пользу от лечения с противораковым лекарственным средством, содержащим антагонист пути wnt, включающий: определение наличия или отсутствия транслокации R-спондина в полученном от индивидуума образце, причем наличие транслокации R-спондина в образце указывает на то, что индивидуум более вероятно будет проявлять пользу от лечения с противораковым лекарственным средством, содержащим антагонист пути wnt, или отсутствие транслокации R-спондина указывает на то, что индивидуум менее вероятно будет проявлять пользу от лечения с противораковым лекарственным средством, содержащим антагонист пути wnt.
7. Способ для прогнозирования того, будет ли более или менее вероятно индивидуум со злокачественной опухолью эффективно отвечать на лечение с противораковым лекарственным средством, содержащим антагонист пути wnt, включающий определение транслокации R-спондина, в результате чего наличие транслокации R-спондина указывает на то, что индивидуум более вероятно будет эффективно отвечать на лечение с антагонистом пути wnt, и отсутствие транслокации R-спондина указывает на то, что индивидуум менее вероятно будет эффективно отвечать на лечение с антагонистом пути wnt.
8. Способ прогнозирования ответной реакции или отсутствия ответной реакции индивидуума со злокачественной опухолью на противораковое лекарственное средство, содержащее антагонист пути wnt, включающий определение в полученном от индивидуума образце наличия или отсутствия транслокации R-спондина, причем наличие транслокации R-спондина прогнозирует ответную реакцию индивидуума на противораковое лекарственное средство, содержащее антагонист пути wnt, и отсутствие транслокации R-спондина прогнозирует отсутствие ответной реакции индивидуума на противораковое лекарственное средство, содержащее антагонист пути wnt.
9. Способ по любому из пп. 1-8, при котором транслокация R-спондина представляет собой транслокацию RSPO1, транслокацию RSPO2, транслокацию RSPO3 и/или транслокацию RSPO4.
10. Способ по п. 9, при котором транслокация R-спондина представляет собой транслокацию RSPO2.
11. Способ по п. 9, при котором транслокация R-спондина представляет собой транслокацию RSPO3.
12. Способ по любому из пп. 1-8, при котором транслокация R-спондина обнаруживается на хромосомном уровне (например, FISH), уровне ДНК, уровне РНК (например, слитый транскрипт транслокации RSPO1) и/или белковом уровне (например, слитый полипептид транслокации RSPO1).
13. Способ по любому из пп. 1-8, при котором злокачественная опухоль или клетка злокачественной опухоли представляет собой злокачественную опухоль толстой и прямой кишок.
14. Способ по любому из пп. 1-8, при котором антагонист пути wnt представляет собой антагонист R-спондина.
15. Способ по п. 14, при котором антагонист пути wnt представляет собой изолированное моноклональное антитело, которое связывает R-спондин.
16. Способ по п. 15, при котором R-спондин представляет собой RSPO2 и/или RSPO3.
17. Способ по любому из пп. 1-8, дополнительно включающий введение дополнительного терапевтического средства.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597746P | 2012-02-11 | 2012-02-11 | |
| US61/597,746 | 2012-02-11 | ||
| US201261674763P | 2012-07-23 | 2012-07-23 | |
| US61/674,763 | 2012-07-23 | ||
| PCT/US2013/025525 WO2013120056A1 (en) | 2012-02-11 | 2013-02-11 | R-spondin translocations and methods using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014133069A true RU2014133069A (ru) | 2016-04-10 |
Family
ID=47750060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014133069A RU2014133069A (ru) | 2012-02-11 | 2013-02-11 | Транслокации r-спондина и способы с их использованием |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20130209473A1 (ru) |
| EP (1) | EP2812350B1 (ru) |
| JP (2) | JP6545959B2 (ru) |
| KR (1) | KR102148303B1 (ru) |
| CN (2) | CN104718220A (ru) |
| AR (1) | AR089978A1 (ru) |
| AU (1) | AU2013216753B2 (ru) |
| BR (1) | BR112014019741A2 (ru) |
| CA (1) | CA2862316A1 (ru) |
| HK (1) | HK1211037A1 (ru) |
| IL (2) | IL233680B (ru) |
| MX (1) | MX366804B (ru) |
| RU (1) | RU2014133069A (ru) |
| SG (1) | SG11201404703WA (ru) |
| WO (1) | WO2013120056A1 (ru) |
| ZA (1) | ZA201406620B (ru) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2173379E (pt) | 2007-07-02 | 2015-11-24 | Oncomed Pharm Inc | Composições e métodos para o tratamento e diagnóstico de cancro |
| CA2841745A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| US9181333B2 (en) | 2012-07-13 | 2015-11-10 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
| CA2888455C (en) | 2012-10-16 | 2021-11-09 | Dna Polymerase Technology, Inc. | Inhibition-resistant polymerases |
| CA2925598A1 (en) | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
| EP3158085B1 (en) | 2014-06-18 | 2020-12-02 | Clear Gene, Inc. | Methods for rapid analysis of biological markers |
| RU2017103289A (ru) | 2014-07-11 | 2018-08-14 | Дженентек, Инк. | Ингибирование пути notch |
| CN106687137A (zh) | 2014-09-16 | 2017-05-17 | 昂考梅德药品有限公司 | 纤维化疾病的治疗 |
| CN116585492A (zh) * | 2014-09-16 | 2023-08-15 | 建新公司 | 用于治疗肌纤蛋白(myoc)青光眼的腺伴随病毒载体 |
| US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
| US11091745B2 (en) | 2015-05-12 | 2021-08-17 | Dna Polymerase Technology, Inc. | Mutant polymerases and uses thereof |
| JP2018522062A (ja) * | 2015-05-26 | 2018-08-09 | キュアジェニックス コーポレーション | 腫瘍バイオマーカー及びその使用 |
| WO2017095918A2 (en) * | 2015-12-01 | 2017-06-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer using rspo3 antagonists |
| CA3008273A1 (en) | 2015-12-18 | 2017-06-22 | Clear Gene, Inc. | Methods, compositions, kits and devices for rapid analysis of biological markers |
| EP3865511A1 (en) | 2016-04-14 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-rspo3 antibodies and methods of use |
| EP3455621B1 (en) * | 2016-05-13 | 2023-07-19 | Cincinnati Children's Hospital Medical Center | Simplification of a septic shock endotyping strategy for clinical application |
| US11104953B2 (en) | 2016-05-13 | 2021-08-31 | Children's Hospital Medical Center | Septic shock endotyping strategy and mortality risk for clinical application |
| BR112019001989A2 (pt) * | 2016-08-02 | 2019-08-20 | Visterra, Inc. | polipeptídeos projetados e usos dos mesmos |
| WO2018039185A1 (en) * | 2016-08-23 | 2018-03-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating estrogen receptor positive breast cancer |
| EP3528841A1 (en) * | 2016-10-20 | 2019-08-28 | The Regents of The University of California | Methods and compositions for the treatment of rna viral infections |
| JP7419068B2 (ja) * | 2016-12-21 | 2024-01-22 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 悪性腫瘍を特定するためのキット及びその使用 |
| US12275994B2 (en) | 2017-06-22 | 2025-04-15 | Clear Gene, Inc. | Methods and compositions for the analysis of cancer biomarkers |
| WO2021070739A1 (ja) * | 2019-10-08 | 2021-04-15 | 国立大学法人 東京大学 | 分析装置、分析方法及びプログラム |
| US11877021B2 (en) | 2019-12-27 | 2024-01-16 | Nippon Hoso Kyokai | Transmitting device and receiving device |
| CN114480632B (zh) * | 2020-11-16 | 2023-05-16 | 江萤 | 人微卫星不稳定位点的检测方法及其应用 |
| CN113957075B (zh) * | 2021-11-22 | 2023-04-07 | 百世诺(北京)医学检验实验室有限公司 | 突变的遗传性心律失常基因及其应用 |
| CN114107482A (zh) * | 2021-11-29 | 2022-03-01 | 百世诺(北京)医学检验实验室有限公司 | 肺动脉高压突变基因及其应用 |
| KR102554222B1 (ko) * | 2023-03-21 | 2023-07-11 | 순천향대학교 산학협력단 | 신규한 항-인간 알스폰딘3 항체 및 이의 용도 |
| KR102551095B1 (ko) * | 2023-03-21 | 2023-07-04 | 순천향대학교 산학협력단 | 신규한 항-인간 알스폰딘2 항체 및 이의 용도 |
| CN119656337A (zh) * | 2024-11-06 | 2025-03-21 | 中山大学附属第六医院 | 肿瘤细胞pcbp1基因突变调控cd8+t细胞在制备免疫治疗药物或制剂中的用途 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
| EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1986005803A1 (fr) | 1985-03-30 | 1986-10-09 | Marc Ballivet | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| ATE176239T1 (de) | 1990-11-21 | 1999-02-15 | Iterex Pharma Lp | Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| EP0760012A4 (en) | 1994-06-10 | 1997-07-02 | Symbiotech Inc | METHODS FOR DETECTING COMPOUNDS BY MEANS OF GENETICALLY MODIFIED LAMBDA BACTERIOPHAGE |
| US5627024A (en) | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ATE239799T1 (de) | 1995-09-07 | 2003-05-15 | Novozymes As | Nachweis der aktivität von enzymen für detergenzien durch phagen. |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| JPH11507246A (ja) | 1996-03-20 | 1999-06-29 | ダイアックス コープ． | 巨大分子用アフィニティ・リガンドの設計 |
| CA2256449A1 (en) | 1996-06-06 | 1997-12-11 | Lajolla Pharmaceutical Company | Apl immunoreactive peptides, conjugates thereof and methods of treatment for apl antibody-mediated pathologies |
| DE69731226T2 (de) | 1996-06-10 | 2006-03-09 | The Scripps Research Institute, La Jolla | Verwendung von substrat-subtraktionsbibliotheken zur unterscheidung von enzymspezifitäten |
| US5766905A (en) | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
| WO1998014277A1 (en) | 1996-10-04 | 1998-04-09 | Whatman, Inc. | Device and method for simultaneous multiple chemical syntheses |
| JP2001512560A (ja) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段 |
| CA2270869A1 (en) | 1996-11-06 | 1998-05-14 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
| IL119587A (en) | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| AU1288399A (en) | 1997-10-29 | 1999-05-17 | Genentech Inc. | Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3 |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| JP2002533726A (ja) | 1998-12-28 | 2002-10-08 | サネシス ファーマシューティカルス インコーポレイテッド | 結合のための小有機分子リガンドの同定 |
| EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2601882T5 (es) | 1999-04-09 | 2021-06-07 | Kyowa Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| US7005499B1 (en) | 1999-11-18 | 2006-02-28 | Genentech, Inc. | Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same |
| AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| DK1242438T3 (da) | 1999-12-29 | 2007-02-12 | Immunogen Inc | Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse |
| JP2003519491A (ja) | 2000-01-13 | 2003-06-24 | ジェネンテック・インコーポレーテッド | 新規なｓｔｒａ６ポリペプチド |
| DK2857516T3 (en) | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| ATE544855T1 (de) | 2000-10-16 | 2012-02-15 | Genentech Inc | Wisp polypeptide, und deren therapeutische anwendungen |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1916303B1 (en) | 2000-11-30 | 2013-02-27 | Medarex, Inc. | Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2481656A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7455834B2 (en) | 2002-06-29 | 2008-11-25 | Genentech, Inc. | Methods and compositions for modulating and detecting WISP activity |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK2289936T3 (en) | 2002-12-16 | 2017-07-31 | Genentech Inc | IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF |
| EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| WO2005025603A2 (en) | 2003-09-11 | 2005-03-24 | Genentech, Inc. | Methods of using wisp antagonists |
| WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
| WO2005035778A1 (ja) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
| ES2437337T3 (es) | 2003-10-10 | 2014-01-10 | Deutsches Krebsforschungszentrum | Composiciones para diagnosis y terapia de enfermedades asociadas con la expresión aberrante de futrinas (R-Espondinas) |
| DK2380910T3 (en) | 2003-11-05 | 2015-10-19 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| PT2489364E (pt) | 2003-11-06 | 2015-04-16 | Seattle Genetics Inc | Compostos de monometilvalina conjugados com anticorpos |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2006235258A1 (en) * | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
| EP1917022A2 (en) | 2005-07-26 | 2008-05-07 | Kirin Pharma Kabushiki Kaisha | Anti-tumor agents comprising r-spondins |
| WO2007030290A2 (en) | 2005-09-07 | 2007-03-15 | Maine Medical Center Research | Cristin/r-spondin ligands active in the wnt signaling pathway and methods, compositions and kits relating thereto |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| EP2002259B1 (en) | 2006-04-10 | 2012-05-16 | Genentech, Inc. | Disheveled PDZ modulators |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| JP2008044926A (ja) | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Ｗｎｔ信号伝達に関係した分泌タンパク質 |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| SG174101A1 (en) | 2006-09-08 | 2011-09-29 | Genentech Inc | Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders |
| CA2664828A1 (en) * | 2006-10-20 | 2008-04-24 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Rspondins as modulators of angiogenesis and vasculogenesis |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| PT2173379E (pt) | 2007-07-02 | 2015-11-24 | Oncomed Pharm Inc | Composições e métodos para o tratamento e diagnóstico de cancro |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| WO2011076932A1 (en) | 2009-12-23 | 2011-06-30 | Deutsches Krebsforschungszentrum | Receptors of rspo2 and rspo3 |
| EP2550295A1 (en) | 2010-03-24 | 2013-01-30 | F. Hoffmann-La Roche AG | Anti-lrp6 antibodies |
-
2013
- 2013-02-11 RU RU2014133069A patent/RU2014133069A/ru not_active Application Discontinuation
- 2013-02-11 SG SG11201404703WA patent/SG11201404703WA/en unknown
- 2013-02-11 CA CA2862316A patent/CA2862316A1/en not_active Abandoned
- 2013-02-11 WO PCT/US2013/025525 patent/WO2013120056A1/en not_active Ceased
- 2013-02-11 JP JP2014556773A patent/JP6545959B2/ja not_active Expired - Fee Related
- 2013-02-11 US US13/764,631 patent/US20130209473A1/en not_active Abandoned
- 2013-02-11 HK HK15111759.1A patent/HK1211037A1/xx unknown
- 2013-02-11 MX MX2014009512A patent/MX366804B/es active IP Right Grant
- 2013-02-11 AU AU2013216753A patent/AU2013216753B2/en not_active Ceased
- 2013-02-11 EP EP13706133.9A patent/EP2812350B1/en active Active
- 2013-02-11 BR BR112014019741-5A patent/BR112014019741A2/pt not_active Application Discontinuation
- 2013-02-11 CN CN201380019639.8A patent/CN104718220A/zh active Pending
- 2013-02-11 KR KR1020147024749A patent/KR102148303B1/ko not_active Expired - Fee Related
- 2013-02-11 CN CN202110410263.XA patent/CN113398268A/zh active Pending
- 2013-02-13 AR ARP130100439A patent/AR089978A1/es unknown
-
2014
- 2014-07-17 IL IL233680A patent/IL233680B/en active IP Right Grant
- 2014-09-10 ZA ZA2014/06620A patent/ZA201406620B/en unknown
-
2017
- 2017-09-14 JP JP2017176424A patent/JP2018021068A/ja active Pending
-
2019
- 2019-06-20 IL IL267560A patent/IL267560A/en unknown
-
2020
- 2020-06-08 US US16/895,395 patent/US20210025008A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL233680A0 (en) | 2014-09-30 |
| JP2018021068A (ja) | 2018-02-08 |
| AU2013216753B2 (en) | 2017-09-21 |
| EP2812350B1 (en) | 2019-04-03 |
| EP2812350A1 (en) | 2014-12-17 |
| AU2013216753A1 (en) | 2014-08-14 |
| KR102148303B1 (ko) | 2020-08-26 |
| ZA201406620B (en) | 2016-08-31 |
| BR112014019741A2 (pt) | 2020-12-22 |
| JP2015513529A (ja) | 2015-05-14 |
| MX2014009512A (es) | 2014-09-12 |
| CA2862316A1 (en) | 2013-08-15 |
| JP6545959B2 (ja) | 2019-07-17 |
| KR20140130461A (ko) | 2014-11-10 |
| CN113398268A (zh) | 2021-09-17 |
| US20130209473A1 (en) | 2013-08-15 |
| HK1211037A1 (en) | 2016-05-13 |
| US20210025008A1 (en) | 2021-01-28 |
| SG11201404703WA (en) | 2014-09-26 |
| WO2013120056A1 (en) | 2013-08-15 |
| MX366804B (es) | 2019-07-25 |
| CN104718220A (zh) | 2015-06-17 |
| AR089978A1 (es) | 2014-10-01 |
| IL267560A (en) | 2019-08-29 |
| IL233680B (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014133069A (ru) | Транслокации r-спондина и способы с их использованием | |
| Cui et al. | A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumours | |
| Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
| Dosset et al. | PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer | |
| Kustanovich et al. | Life and death of circulating cell-free DNA | |
| JP2015513529A5 (ru) | ||
| Sauer et al. | Innovative approaches in the battle against cancer recurrence: novel strategies to combat dormant disseminated tumor cells | |
| Tse et al. | Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality | |
| Zang et al. | CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway | |
| Yuzhalin et al. | Brain metastasis organotropism | |
| Bulk et al. | Epigenetic dysregulation of KCa3. 1 channels induces poor prognosis in lung cancer | |
| Park et al. | Apoptosis-induced nuclear expulsion in tumor cells drives S100a4-mediated metastatic outgrowth through the RAGE pathway | |
| Kikuchi et al. | A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8 (+) TILs together with up-regulated IFN-γ | |
| Yamamoto et al. | Orchestration of collective migration and metastasis by tumor cell clusters | |
| Patel et al. | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer | |
| Wang et al. | High-throughput chemical screening identifies focal adhesion kinase and Aurora kinase B inhibition as a synergistic treatment combination in Ewing sarcoma | |
| Harris et al. | CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance | |
| Lee et al. | KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers | |
| RU2018112516A (ru) | Метод | |
| RU2015102194A (ru) | Способы лечения связанных с fgfr3 состояний | |
| Dominguez et al. | Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies | |
| JP2017516458A5 (ru) | ||
| Lapitz et al. | Extracellular vesicles in hepatobiliary malignancies | |
| Dreyling et al. | New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature? | |
| Mereu et al. | The heterogeneous landscape of ALK negative ALCL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180110 |